{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:17:56Z","timestamp":1788866276149,"version":"build-2803163510"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.phrs.2026.108237","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:25:52Z","timestamp":1778577952000},"page":"108237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["FDA-approved RET protein-tyrosine kinase inhibitors in the management of RET-driven thyroid and lung cancer"],"prefix":"10.1016","volume":"229","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9861-4139","authenticated-orcid":false,"suffix":"Jr.","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.108237_bib1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0092-8674(85)90115-1","article-title":"Activation of a novel human transforming gene, ret, by DNA rearrangement","volume":"42","author":"Takahashi","year":"1985","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108237_bib2","first-page":"1519","article-title":"Human ret proto-oncogene mapped to chromosome 10q11.2","volume":"4","author":"Ishizaka","year":"1989","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2026.108237_bib3","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/381789a0","article-title":"GDNF signalling through the Ret receptor tyrosine kinase","volume":"381","author":"Durbec","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108237_bib4","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","article-title":"The importance of the RET gene in thyroid cancer and therapeutic implications","volume":"17","author":"Salvatore","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.phrs.2026.108237_bib5","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108237_bib6","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.3390\/ijms27073180","article-title":"RET signaling pathway in human cancer: oncogenic mechanisms, selective inhibitors, and emerging resistance strategies","volume":"27","author":"Streit","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108237_bib7","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108237_bib8","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.molcel.2014.01.015","article-title":"Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans","volume":"6","author":"Plaza-Menacho","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2026.108237_bib9","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.cellsig.2014.03.032","article-title":"Mechanisms of RET signaling in cancer: current and future implications for targeted therapy","volume":"26","author":"Plaza-Menacho","year":"2014","journal-title":"Cell. Signal."},{"key":"10.1016\/j.phrs.2026.108237_bib10","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1016\/j.celrep.2016.11.061","article-title":"RET Functions as a dual-specificity kinase that requires allosteric inputs from juxtamembrane elements","volume":"17","author":"Plaza-Menacho","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.phrs.2026.108237_bib11","doi-asserted-by":"crossref","first-page":"14213","DOI":"10.1074\/jbc.M312600200","article-title":"Identification of RET autophosphorylation sites by mass spectrometry","volume":"279","author":"Kawamoto","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2026.108237_bib12","doi-asserted-by":"crossref","first-page":"35808","DOI":"10.1074\/jbc.M104968200","article-title":"Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site","volume":"276","author":"Anders","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2026.108237_bib13","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1096\/fasebj.9.8.7768349","article-title":"Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification","volume":"9","author":"Hanks","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2026.108237_bib14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108237_bib15","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1126\/science.1862343","article-title":"Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108237_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib17","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2174\/1568026617666170224121313","article-title":"Structure-based virtual screening approaches in kinase-directed drug discovery","volume":"17","author":"Bajusz","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108237_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib19","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1098\/rstb.2012.0054","article-title":"Evolution of the eukaryotic protein kinases as dynamic molecular switches","volume":"367","author":"Taylor","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.phrs.2026.108237_bib20","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.molcel.2004.08.024","article-title":"Regulation of protein kinases; controlling activity through activation segment conformation","volume":"15","author":"Nolen","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2026.108237_bib21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bbrc.2011.11.145","article-title":"MEK1\/2 dual-specificity protein kinases: structure and regulation","volume":"417","author":"Roskoski","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2026.108237_bib22","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1634\/theoncologist.2013-0095","article-title":"Novel targets in non-small cell lung cancer: ROS1 and RET fusions","volume":"18","author":"Gainor","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.phrs.2026.108237_bib23","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nrc3612","article-title":"Tyrosine kinase gene rearrangements in epithelial malignancies","volume":"13","author":"Shaw","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2026.108237_bib24","doi-asserted-by":"crossref","first-page":"15733","DOI":"10.1021\/bi971438n","article-title":"Participation of ADP dissociation in the rate-determining step in cAMP-dependent protein kinase","volume":"36","author":"Zhou","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2026.108237_bib25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1126\/science.3291115","article-title":"The protein kinase family: conserved features and deduced phylogeny of the catalytic domains","volume":"241","author":"Hanks","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108237_bib26","doi-asserted-by":"crossref","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.phrs.2026.108237_bib27","doi-asserted-by":"crossref","first-page":"14377","DOI":"10.1073\/pnas.0807988105","article-title":"A helix scaffold for the assembly of active protein kinases","volume":"105","author":"Kornev","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.phrs.2026.108237_bib28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.phrs.2014.06.001","article-title":"ErbB\/HER protein-tyrosine kinases: Structure and small molecule inhibitors","volume":"87","author":"Roskoski","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107983","article-title":"Vascular endothelial cells and angiogenesis","volume":"221","author":"Roskoski","year":"2025","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2017.01.007","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107723","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update","volume":"216","author":"Roskoski","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib34","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1517\/17460441.2013.813015","article-title":"The preclinical profile of crizotinib in the treatment of non-small cell lung cancer and other neoplastic disorders","volume":"8","author":"Roskoski","year":"2013","journal-title":"Expert Opin. Drug Dis."},{"key":"10.1016\/j.phrs.2026.108237_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105660","article-title":"Hydrophobic and polar interactions of FDA-approved small molecule protein kinase inhibitors with their target enzymes","volume":"169","author":"Roskoski","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104567","article-title":"The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder","volume":"151","author":"Roskoski","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.phrs.2018.01.021","article-title":"The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders","volume":"129","author":"Roskoski","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2018.04.020","article-title":"The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders","volume":"133","author":"Roskoski","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104725","article-title":"The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias","volume":"155","author":"Roskoski","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib41","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2017.04.022","article-title":"ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers","volume":"121","author":"Roskoski","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib42","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib43","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","article-title":"Targeting oncogenic Raf protein-serine\/threonine kinases in human cancers","volume":"135","author":"Roskoski","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106362","article-title":"Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders","volume":"183","author":"Roskoski","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2026.108187","article-title":"Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders","volume":"227","author":"Roskoski","year":"2026","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib46","series-title":"Reference module in life sciences","first-page":"1","article-title":"Src family tyrosine kinases","author":"Frame","year":"2017"},{"key":"10.1016\/j.phrs.2026.108237_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106156","article-title":"Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia","volume":"178","author":"Roskoski","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib48","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2016.12.009","article-title":"Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib49","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.phrs.2016.03.012","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs","volume":"107","author":"Roskoski","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib50","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108237_bib51","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.phrs.2019.01.039","article-title":"Targeting ERK1\/2 protein-serine\/threonine kinases in human cancers","volume":"142","author":"Roskoski","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2026.108237_bib53","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0968-0896(98)00099-6","article-title":"A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src","volume":"6","author":"Liu","year":"1998","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108237_bib54","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1021\/jm0608107","article-title":"Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors","volume":"50","author":"Liao","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108237_bib55","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1073\/pnas.94.8.3565","article-title":"Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates","volume":"94","author":"Shah","year":"1997","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.phrs.2026.108237_bib56","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/jm400378w","article-title":"KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space","volume":"57","author":"van Linden","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108237_bib57","doi-asserted-by":"crossref","first-page":"D562","DOI":"10.1093\/nar\/gkaa895","article-title":"KLIFS: an overhaul after the first 5 years of supporting kinase research","volume":"49","author":"Kanev","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2026.108237_bib58","doi-asserted-by":"crossref","first-page":"D654","DOI":"10.1093\/nar\/gkab920","article-title":"Kincore: a web resource for structural classification of protein kinases and their inhibitors","volume":"50","author":"Modi","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2026.108237_bib59","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2026.108237_bib60","series-title":"The MD Anderson Manual of Medical Oncology","first-page":"1189","article-title":"Endocrine Malignancies","author":"Nguyen","year":"2022"},{"key":"10.1016\/j.phrs.2026.108237_bib61","doi-asserted-by":"crossref","first-page":"175","DOI":"10.31662\/jmaj.2020-0021","article-title":"Roles of the RET Proto-oncogene in cancer and development","volume":"3","author":"Takahashi","year":"2020","journal-title":"JMA J."},{"key":"10.1016\/j.phrs.2026.108237_bib62","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2183\/pjab.98.008","article-title":"RET receptor signaling: Function in development, metabolic disease, and cancer","volume":"98","author":"Takahashi","year":"2022","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.phrs.2026.108237_bib63","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jfma.2025.06.033","article-title":"Four decades of the RET gene: from discovery to tumor-agnostic therapy","volume":"124","author":"Takahashi","year":"2025","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.phrs.2026.108237_bib64","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/biomedicines14010168","article-title":"State of the art on thyroid cancer biology and oncology","volume":"14","author":"Vaio","year":"2026","journal-title":"Biomedicines"},{"key":"10.1016\/j.phrs.2026.108237_bib65","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyag017","article-title":"Multidisciplinary team diagnosis and treatment of well-differentiated thyroid carcinoma: current landscape and future prospects","volume":"31","author":"Li","year":"2026","journal-title":"Oncologist"},{"key":"10.1016\/j.phrs.2026.108237_bib66","article-title":"Molecular pathogenesis and therapeutic advances in RET fusion-positive papillary thyroid carcinoma","volume":"281","author":"Wei","year":"2026","journal-title":"Pathol. Res. Pr."},{"key":"10.1016\/j.phrs.2026.108237_bib67","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(23)00020-X","article-title":"Thyroid cancer","volume":"401","author":"Chen","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108237_bib68","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1177\/10507256251390877","article-title":"Executive summary of the 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Praw","year":"2025","journal-title":"Thyroid"},{"key":"10.1016\/j.phrs.2026.108237_bib69","first-page":"68","article-title":"The role of 123I in the management of differentiated thyroid cancer: a comprehensive narrative review","volume":"14","author":"Bellini","year":"2026","journal-title":"Med. Sci."},{"key":"10.1016\/j.phrs.2026.108237_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1176731","article-title":"Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance","volume":"14","author":"Hamidi","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.phrs.2026.108237_bib71","doi-asserted-by":"crossref","first-page":"7072","DOI":"10.1097\/JS9.0000000000002816","article-title":"Dynamic risk stratification-guided management of medullary thyroid carcinoma: integrating surgical precision with RET-targeted therapies and molecular surveillance","volume":"111","author":"Zhang","year":"2025","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.phrs.2026.108237_bib72","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrendo.2016.11","article-title":"A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma","volume":"12","author":"Romei","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.phrs.2026.108237_bib73","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.3390\/genes16121472","article-title":"RET gene alterations in clinical practice: a comprehensive review and database update","volume":"16","author":"Ricciardi Tenore","year":"2025","journal-title":"Genes"},{"key":"10.1016\/j.phrs.2026.108237_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2026.105329","article-title":"Pediatric thyroid cancer: Distinct pathogenesis, emerging therapeutic strategies and long-term survivorship management","volume":"223","author":"Zhan","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.phrs.2026.108237_bib75","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/cncr.28661","article-title":"RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma","volume":"120","author":"Krampitz","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2026.108237_bib76","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nrclinonc.2017.188","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2026.108237_bib77","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1056\/NEJMra1501993","article-title":"Biologic and clinical perspectives on thyroid cancer","volume":"375","author":"Fagin","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108237_bib78","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35779","article-title":"Treatment of non-small cell lung cancer with RET rearrangements","volume":"131","author":"Hoe","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2026.108237_bib79","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib80","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/med.21409","article-title":"Approved and experimental small-molecule oncology kinase inhibitor drugs: a mid-2016 overview","volume":"37","author":"Fischer","year":"2017","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.phrs.2026.108237_bib81","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/13543776.2017.1238073","article-title":"RET kinase inhibitors: a review of recent patents (2012-2015)","volume":"27","author":"Mologni","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.phrs.2026.108237_bib82","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/14656566.2017.1340939","article-title":"Advances in small molecule therapy for treating metastatic thyroid cancer","volume":"18","author":"Krajewska","year":"2017","journal-title":"Expert Opin. Pharm."},{"key":"10.1016\/j.phrs.2026.108237_bib83","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1080\/14796694.2025.2508132","article-title":"Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion-positive non-small cell lung cancer","volume":"21","author":"Hochmair","year":"2025","journal-title":"Future Oncol."},{"key":"10.1016\/j.phrs.2026.108237_bib84","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s40265-020-01343-7","article-title":"Selpercatinib: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2026.108237_bib85","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-020-01427-4","article-title":"Pralsetinib: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2026.108237_bib86","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1146\/annurev-biochem-090308-173656","article-title":"The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling","volume":"80","author":"Dar","year":"2011","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.phrs.2026.108237_bib87","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0022-2836(63)80091-1","article-title":"Allosteric proteins and cellular control systems","volume":"6","author":"Monod","year":"1963","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2026.108237_bib88","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1021\/jm901443h","article-title":"Through the \"gatekeeper door\": exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108237_bib89","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1039\/C2MD20180A","article-title":"Approaches to discover non-ATP site inhibitors","volume":"4","author":"Gavrin","year":"2013","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.phrs.2026.108237_bib90","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.2174\/138161212800672813","article-title":"New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors","volume":"18","author":"Lamba","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2026.108237_bib91","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2174\/156802607781696783","article-title":"Targeting protein multiple conformations: a structure-based strategy for kinase drug design","volume":"7","author":"Liao","year":"2007","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108237_bib92","doi-asserted-by":"crossref","first-page":"D365","DOI":"10.1093\/nar\/gkv1082","article-title":"KLIFS: a structural kinase-ligand interaction database","volume":"44","author":"Kooistra","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2026.108237_bib93","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1021\/acschembio.9b00476","article-title":"Surprising non-additivity of methyl groups in drug-kinase interaction","volume":"14","author":"Wienen-Schmidt","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2026.108237_bib94","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.tips.2019.09.002","article-title":"The landscape of atypical and eukaryotic protein kinases","volume":"40","author":"Kanev","year":"2019","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.phrs.2026.108237_bib95","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.phrs.2026.108237_bib96","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2026.108237_bib97","doi-asserted-by":"crossref","first-page":"33577","DOI":"10.1074\/jbc.M605604200","article-title":"Structure and chemical inhibition of the RET tyrosine kinase domain","volume":"281","author":"Knowles","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2026.108237_bib98","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221101691","article-title":"RET kinase inhibitors for RET-altered thyroid cancers","volume":"14","author":"Vodopivec","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.phrs.2026.108237_bib99","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3892\/mmr.2026.13874","article-title":"Mechanism of and research progress on alterations in the RET gene in thyroid cancer (Review)","volume":"33","author":"Wei","year":"2026","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.phrs.2026.108237_bib100","doi-asserted-by":"crossref","first-page":"10741","DOI":"10.1158\/0008-5472.CAN-06-3329","article-title":"Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B","volume":"66","author":"Gujral","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2026.108237_bib101","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4274\/Jcrpe.870","article-title":"RET gene abnormalities and thyroid disease: who should be screened and when","volume":"5","author":"Salehian","year":"2013","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"key":"10.1016\/j.phrs.2026.108237_bib102","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1200\/JCO.2008.21.2134","article-title":"American Society of Clinical Oncology, Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology","volume":"27","author":"Winer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2026.108237_bib103","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004652","article-title":"Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer","volume":"6","author":"Niederst","year":"2013","journal-title":"Sci. Signal"},{"key":"10.1016\/j.phrs.2026.108237_bib104","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases \u2013 the major drug targets of the twenty-first century","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2026.108237_bib105","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2026.108237_bib106","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2026.108237_bib107","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/d41573-025-00188-7","article-title":"FDA approves 100th small-molecule kinase inhibitor","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2026.108237_bib108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181585","article-title":"Progress towards a public chemogenomic set for protein kinases and a call for contributions","volume":"12","author":"Drewry","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2026.108237_bib109","doi-asserted-by":"crossref","first-page":"136","DOI":"10.33594\/000000858","article-title":"mTOR signalling in neurodegenerative disorders: unveiling key factors, mechanistic insights, and possible therapeutic interventions","volume":"60","author":"Jha","year":"2026","journal-title":"Cell Physiol. Biochem."},{"key":"10.1016\/j.phrs.2026.108237_bib110","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2217\/fca.11.51","article-title":"Rho kinase as a therapeutic target in cardiovascular disease","volume":"7","author":"Surma","year":"2011","journal-title":"Future Cardiol."},{"key":"10.1016\/j.phrs.2026.108237_bib111","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3389\/fphar.2018.01083","article-title":"Fasudil, a Rho-kinase inhibitor, exerts cardioprotective function in animal models of myocardial ischemia\/reperfusion injury: a meta-analysis and review of preclinical evidence and possible mechanisms","volume":"9","author":"Huang","year":"2018","journal-title":"Front. Pharm."},{"key":"10.1016\/j.phrs.2026.108237_bib112","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000001038","article-title":"Protein kinase inhibitors in heart failure: mechanistic insights and therapeutic prospects","author":"Ahmad","year":"2025","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.phrs.2026.108237_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2026.108107","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2026 update","volume":"224","author":"Roskoski","year":"2026","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib114","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10689-025-00440-4","article-title":"Progress report on multiple endocrine neoplasia type 1","volume":"24","author":"Halperin","year":"2025","journal-title":"Fam. Cancer"},{"key":"10.1016\/j.phrs.2026.108237_bib115","doi-asserted-by":"crossref","first-page":"R71","DOI":"10.1093\/ejendo\/lvaf247","article-title":"New directions in MEN1 management: navigating the new clinical practice guidelines","volume":"193","author":"Papalou","year":"2025","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.phrs.2026.108237_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107534","article-title":"Targeted and cytotoxic inhibitors used in the treatment of breast cancer","volume":"210","author":"Roskoski","year":"2024","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107181","article-title":"Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas","volume":"203","author":"Roskoski","year":"2024","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107465","article-title":"Targeted and cytotoxic inhibitors used in the treatment of lung cancers","volume":"209","author":"Roskoski","year":"2024","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108237_bib119","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.phrs.2017.02.005","article-title":"Guidelines for preparing color figures for everyone including the colorblind","volume":"119","author":"Roskoski","year":"2017","journal-title":"Pharm. Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826001520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826001520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:27:06Z","timestamp":1781454426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826001520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":119,"alternative-id":["S1043661826001520"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108237","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FDA-approved RET protein-tyrosine kinase inhibitors in the management of RET-driven thyroid and lung cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108237","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108237"}}